Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Merck KGaA
The latest accelerated approval withdrawals in the US are milestones for accountability in the program – most notably with the withdrawal of an antimicrobial with confirmatory studies more than a decade overdue.
The gene therapy firm announced that Bristol terminated a collaboration started in 2015. Nona follows its recent alliance with Moderna with a second collaboration, this time with Dragonfly.
The move marks the second time since last year that Roche has withdrawn a urothelial carcinoma indication after its confirmatory trial failed to show an overall survival benefit.
Medtech Insight followed-up with Cordis CEO Shar Matin to talk about the company’s path forward as an innovative intervention company following the acquisition of MedAlliance.
- Research, Analytical Equipment & Supplies
- Drug Delivery
- Synthesis Technologies, Production Processes
Drug Discovery Tools
- Natural Products
- Molecular Diversity
- Other Names / Subsidiaries
- Acadiana Ventures Inc.
- Allergopharma Joachim Ganzer KG
- AmpTec GmbH
- Chord Therapeutics SA
- EMD Pharmaceuticals
- Grzybowski Scientific Inventions (GSI)
- Intermolecular Inc
- JRH Biosciences
- Merck Hoei Ltd.
- Ormet Circuts Inc.
- EMD Serono, Inc.
- Versum Materials, Inc.